GE touts Omnipaque taste test

GE Healthcare of Chalfont St. Giles, U.K., said that a head-to-head taste test of oral contrast agents found a significantly greater preference for its Omnipaque agent (iohexol) compared to Covidien's Gastroview (diluted diatrizoate sodium).

The study, published in the November issue of the American Journal of Roentgenology, also found no significant differences between the agents in terms of side effects or bowel opacification, according to lead author Michelle McNamara, MD, of the University of Alabama at Birmingham.

The prospective, double-blind study included 300 adult patients.

Related Reading

GE to continue health academy support, November 9, 2010

GE wins 7T Wis. MRI contract, November 5, 2010

GE inks consulting deal with West Physics, November 4, 2010

GE shows MRI options, software at ASTRO, November 3, 2010

Study: Patients prefer iohexol contrast taste, March 3, 2010

Copyright © 2010 AuntMinnie.com

Page 1 of 654
Next Page